Fig. 4
From: Generation and purification of iPSC-derived cardiomyocytes for clinical applications
Purified human iPSC-derived cardiomyocytes are a safe cell source for in vivo application. (A) Schematic representation of the experimental setup. B + C) Flow cytrometry dot plot of iCMs and iPSC before (upper row) and after (lower row) purification. The proportion of artificially mixed iPS cells in the iCMs is 10% (B) and 50% (C) respectively. Pie charts show percentage of iCMs (red, cTNT positive) and iPSC (blue, Oct4 positive) for the respective marker. (D) Measurement of the volume (mm3) over time after injecting subcutaneously matrigel containing either iCMs (1,000,000 cells) or iPSCs (200,000 cells) using an immunodeficient NSG mouse model. (n = 5) (E) Summary of the tumor formation after subcutaneous injection of iCMs and iPSCs. One representative clone is shown in Fig. 4 (DW4)